Utilization of the ketogenic diet for adults with status epilepticus.

Jun 05, 2023

Experts: Fernanda J P Teixeira,Jacqueline Shannon,Katharina M Busl,Christopher P Robinson,Bakhtawar Ahmed,Jason Katz,Guanhong Miao,Jenna Seckar,Maria Bruzzone,Mackenzie C Cervenka,Carolina B Maciel

The ketogenic diet (KD) is a high-fat, low-carbohydrate diet with therapeutic potential in refractory seizures, both in outpatient and inpatient settings. Successful implementation of KD involves a multifaceted, interdisciplinary approach to address anticipated challenges. We sought to characterize the utilization of KD among healthcare providers caring for adults with status epilepticus (SE).
We distributed a web-based survey through professional societies, including the American Academy of Neurology (AAN), Neurocritical Care Society (NCS), American Epilepsy Society (AES), Neuro Anesthesia and Critical Care Society (NACCS), and the Academy of Nutrition and Dietetics (AND), and via research contacts. We asked respondents about practice experience and experience using KD as a treatment for SE. Descriptive statistics and Chi-square tests were used to analyze the results.
Of 156 respondents, 80% of physicians and 18% of non-physicians reported experience with KD for SE. Anticipated difficulty in achieving ketosis (36.3%), lack of expertise (24.2%), and lack of resources (20.9%) were identified as the most important barriers limiting the utilization of KD. The absence of dietitians (37.1%) or pharmacists (25.7%) support was the most important missing resource. Reasons for stopping KD included perceived ineffectiveness (29.1%), difficulty achieving ketosis (24.6%), and side effects (17.3%). Academic centers had more experience with the use of KD and greater EEG monitoring availability and fewer barriers to its implementation. The need for randomized clinical trials supporting efficacy (36.5%) and better practice guidelines for implementation and maintenance of KD (29.6%) were cited most frequently as factors to increase utilization of KD.
This study identifies important barriers to the utilization of KD as a treatment for SE despite evidence supporting its efficacy in the appropriate clinical context, namely lack of resources and interdisciplinary support, and lack of established practice guidelines. Our results highlight the need for future research to improve understanding of the efficacy and safety of KD along with better interdisciplinary collaborations to increase its utilization.

Copyright © 2023 Elsevier Inc. All rights reserved.

Author

admin

View all posts

ABOUT THE EXPERTS

Fernanda J P Teixeira,Jacqueline Shannon,Katharina M Busl,Christopher P Robinson,Bakhtawar Ahmed,Jason Katz,Guanhong Miao,Jenna Seckar,Maria Bruzzone,Mackenzie C Cervenka,Carolina B Maciel

Fernanda J P Teixeira

Department of Neurology, Division of Neurocritical Care, University of Florida College of Medicine, Gainesville, FL 32611, USA; Department of Neurology, University of Miami, Miami, FL 33136, USA.

Jacqueline Shannon

State University of New York College of Optometry, New York, NY 10036, USA.

Katharina M Busl

Department of Neurology, Division of Neurocritical Care, University of Florida College of Medicine, Gainesville, FL 32611, USA; Department of Neurosurgery, University of Florida, College of Medicine, Gainesville, FL 32611, USA.

Christopher P Robinson

Department of Neurology, Division of Neurocritical Care, University of Florida College of Medicine, Gainesville, FL 32611, USA; Department of Neurosurgery, University of Florida, College of Medicine, Gainesville, FL 32611, USA.

Bakhtawar Ahmed

Department of Neurology, Division of Neurocritical Care, University of Florida College of Medicine, Gainesville, FL 32611, USA.

Jason Katz

Department of Neurology, Division of Neurocritical Care, University of Florida College of Medicine, Gainesville, FL 32611, USA.

Guanhong Miao

Department of Biostatistics, University of Florida, Gainesville, FL 32611, USA.

Jenna Seckar

University of Florida Health Shands Hospital, Gainesville, FL 32610, USA.

Maria Bruzzone

Department of Neurology, Division of Epilepsy, University of Florida College of Medicine, Gainesville, FL 32611, USA.

Mackenzie C Cervenka

Department of Neurology, Division of Epilepsy, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Carolina B Maciel

Department of Neurology, Division of Neurocritical Care, University of Florida College of Medicine, Gainesville, FL 32611, USA; Department of Neurosurgery, University of Florida, College of Medicine, Gainesville, FL 32611, USA; Department of Neurology, Division of Epilepsy, University of Florida College of Medicine, Gainesville, FL 32611, USA; Department of Neurology, Yale University School of Medicine, New Haven, CT 06520, USA; Department of Neurology, University of Utah, Salt Lake City, UT 84132, USA. Electronic address: Carolina.Maciel@neurology.ufl.edu.